Last reviewed · How we verify
Pertussis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Benzamycin | Erythromycin Lactobionate | Pfizer | Macrolide | Potassium voltage-gated channel subfamily H member 2 | 1964-01-01 | |
| E-Mycin | erythromycin | Generic (originally Abbott/Lilly) | Macrolide [EPC] | Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1 | 1952-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Abbott/Lilly) · 1 drug in Pertussis
- Pfizer · 1 drug in Pertussis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Pertussis:
- Pertussis treatment updates — RSS
- Pertussis treatment updates — Atom
- Pertussis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Pertussis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pertussis. Accessed 2026-06-10.
Related
- Pertussis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing